EXPERT OPINION ON BIOLOGICAL THERAPY

简称 EXPERT OPIN BIOL TH ·ENGLAND ·出版周期 Bimonthly ·年均收录 127 篇

4.0

最新影响因子

2.60%

自引率

较易

投稿难度

一般,3-8周

审稿周期

期刊简介

EXPERT OPINION ON BIOLOGICAL THERAPY是一本专注于生物治疗领域的国际期刊，ISSN号为1471-2598，由英国出版商TAYLOR & FRANCIS出版，出版地为英国，出版周期为月刊。该期刊的影响因子较高，具体数值需参考最新JCR报告，属于SCI收录期刊，中科院分区情况需根据每年更新的大类和小类分区确认，目前为非开放获取（非OA）期刊。该期刊的发文特点集中于生物治疗的前沿研究，包括基因治疗、细胞治疗、抗体治疗等领域，尤其注重专家评论和综述类文章，旨在为学术界和产业界提供权威的学术观点。杂志的质量较高，审稿严格，但作为综述类期刊，其原创性研究相对较少，可能存在发表周期较长或竞争激烈的风险，需结合具体研究方向评估投稿价值。

影响因子趋势

近期发表

Gene-edited hypoimmune islets as a cure for type 1 diabetes: a review of the immunological challenges 2026-08-21

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis 2026-08-29

Developability-by-design for bispecific antibodies in discovery: combining computational prediction and early screening for candidate selection 2026-08-31

Repositioning omalizumab in dermatology: emerging indications and mechanism-based therapeutic insights 2026-08-28

Efficacy of nipocalimab in patients with moderate-to-severe ocular symptoms of generalized myasthenia gravis in the phase 3 Vivacity-MG3 study 2026-09-01

The role of biologics in aspirin-exacerbated respiratory disease 2026-08-25

B-cell depletion therapy in systemic lupus erythematosus: emerging strategies and challenges 2026-08-28

An evaluation of becotatug vedotin for the treatment of recurrent or metastatic nasopharyngeal cancer 2026-08-24

Dupilumab versus omalizumab in chronic rhinosinusitis with nasal polyps and asthma: a plain language summary 2026-08-26

Comparable long-term outcomes with biosimilar and originator adalimumab in juvenile idiopathic arthritis: a multicenter cohort study 2026-08-26